Cato, Take Two
Last week some analysts at the Cato Institute surprised me by endorsing trade barriers in the medicine market. Today the other shoe dropped: Cato's president and one of its vice presidents came down on the other side of the issue, with a well-reasoned case for pharmaceutical free trade.
